SAMe

SAMe is a supplement formed in the body by an enzymatic reaction between adenosine-triphosphate (ATP) and methionine.  It was discovered in 1952 in Italy and has been researched and manufactured there.  SAMe works closely with folic acid and vitamin B-12 and functions as a methyl donor.  This nutrient carries and donates methyl molecules necessary to facilitate the manufacture of DNA and brain neurotransmitters.* Tissue levels of SAMe are typically low in the elderly.

SAMe (S-adenosylmethionine), a compound native to the body, is a critical component of many biochemical reactions, including those that affect brain biochemistry and joint health.  Numerous studies have indicated that SAMe can help to temporarily alleviate minor joint discomfort resulting from overexertion or stress.    In addition, because SAMe is also necessary for the synthesis of neurotransmitters, it plays an important role in mood support.  SAMe is enteric-coated, which makes it very well tolerated and protects it from degradation.*


SAMe 100 mg  30 tablets         $18.95      

SAMe 400 mg 60 tablets           $57.95     


Count:  30 or 60 Tablets

 

Suggested Use: Take 1 tablet daily, preferably on an empty stomach. Refrigeration recommended after opening.
 
Each Tablet Contains: SAMe (S-Adenosyl-L-Methionine) (from 800 mg of S-Adenosyl-L-Methionine Disulfate Tosylate) 100 mg or 400 mg.
 
Other Ingredients: Cellulose, Croscarmellose Sodium Methacrylic Acid, Magnesium Stearate (vegetable source), Silica, Triethyl Citrate, Stearic Acid (vegetable source), Citric Acid and Ascorbic Acid.

Warning:  Individuals with bipolar (manic) depression should not take SAMe unless under professional supervision.

Disclaimers:  *These statements have not been evaluated by the FDA.  This product is not intended to diagnose, treat, cure or prevent any disease. 

 
 
 

Copyright 2007   SuperSpectrim.com   All rights reserved                Home    Product Catalog    Samples    About Us    FAQ    Articles    Nutrition Info    Contact Us    Testimonials    News Letter